ALCJ.PA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Instruments & Supplies

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$61M	+122.7%	$0.41	$0.27–$0.55	—	1
2027	$42M	-30.4%	$0.52	$0.34–$0.70	—	1
2028	$56M	+31.4%	$0.72	$0.48–$0.96	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ALCJ.PACrossject S.A.	$1.31	+0.15%	$79M	—
ABNX.PAABIONYX Pharma S.A.	$1.67	-1.18%	$71M	—
AB.PAAB Science S.A.	$0.70	-2.36%	$51M	—
ADOC.PAAdocia S.A.	$3.66	+3.33%	$73M	—
AFME.PAAffluent Medical S.A.	$2.81	+0.00%	$110M	—
ALECR.PAEurofins-Cerep S.A.	$16100.00	+0.00%	$81M	—
ALKLH.PAKlea Holding	$0.15	-8.38%	$45M	—

Source: Financial Modeling Prep · peers by sector/industry

Crossject S.A.

Crossject S.A. is dedicated to pioneering needle-free drug delivery solutions. A key innovation from the company is ZENEO, a prefilled, single-use auto-injector that eliminates the need for a traditional needle. Crossject is actively advancing a portfolio of drugs through clinical trials, all intended for administration via its ZENEO system. This pipeline includes Sumatriptan for treating migraines and cluster headaches, Adrenaline for severe allergic reactions (anaphylactic shock), Hydrocortisone for acute adrenal insufficiency, Midazolam for managing epileptic seizures, Naloxone for opioid overdose, Apomorphine for temporary paralysis in Parkinson's patients, Methotrexate for rheumatoid arthritis, and Terbutaline for acute asthma attacks. Founded in 1997, the company maintains its operational base in Dijon, France.

www.crossject.com

Employees: 99
IPO / List date: Feb 20, 2014
HQ: FR

Held by traders on TradeandTell

No one on the platform currently holds ALCJ.PA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ALCJ.PA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ALCJ.PA yet.